Third Wave's Q3 Revenues Grow 24 Percent, Loss Rises | GenomeWeb
NEW YORK (GenomeWeb News) — Third Wave Technologies today said third-quarter revenues grew 24 percent as R&D spending rose 68 percent and its net loss widened 25 percent. 
 
Total receipts for the three months ended Sept. 30 increased to $8.2 million from $6.6 million year over year.
 
Revenue from clinical products rose 25 percent to $6.7 million, while receipts from research products increased 19 percent to $1.4 million.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.